Raymond James Trust N.A. lessened its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 6.9% during the 4th quarter, HoldingsChannel reports. The fund owned 45,477 shares of the company’s stock after selling 3,365 shares during the period. Raymond James Trust N.A.’s holdings in Eli Lilly And Co were worth $5,977,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LLY. Nuveen Asset Management LLC grew its stake in Eli Lilly And Co by 20,030.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after acquiring an additional 7,229,751 shares in the last quarter. AQR Capital Management LLC grew its stake in Eli Lilly And Co by 53.3% during the 2nd quarter. AQR Capital Management LLC now owns 4,335,702 shares of the company’s stock valued at $480,048,000 after acquiring an additional 1,507,050 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Eli Lilly And Co during the 3rd quarter valued at about $101,403,000. BlackRock Inc. grew its stake in Eli Lilly And Co by 1.5% during the 2nd quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after acquiring an additional 898,845 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. grew its stake in Eli Lilly And Co by 13.2% during the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 5,422,106 shares of the company’s stock valued at $600,715,000 after acquiring an additional 632,573 shares in the last quarter. 76.45% of the stock is currently owned by institutional investors.

Shares of LLY stock traded up $1.71 during trading hours on Tuesday, reaching $140.65. 4,685,201 shares of the company’s stock were exchanged, compared to its average volume of 3,570,600. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $140.90. The stock has a market capitalization of $132.50 billion, a P/E ratio of 25.34, a P/E/G ratio of 1.80 and a beta of 0.20. The business has a fifty day moving average price of $126.70 and a 200-day moving average price of $115.12. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The company had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the company earned $1.39 earnings per share. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly And Co will post 5.8 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 14th will be given a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a yield of 2.10%. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date is Thursday, February 13th. Eli Lilly And Co’s dividend payout ratio is 46.49%.

Several equities analysts have weighed in on LLY shares. Argus lifted their target price on Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, December 30th. Bank of America assumed coverage on Eli Lilly And Co in a research note on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target for the company. UBS Group lowered their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research note on Thursday, October 17th. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b-” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $143.00 price target on shares of Eli Lilly And Co in a research note on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $135.67.

In other Eli Lilly And Co news, SVP Anne E. White bought 1,000 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were bought at an average price of $108.84 per share, for a total transaction of $108,840.00. Following the completion of the acquisition, the senior vice president now owns 22,043 shares of the company’s stock, valued at $2,399,160.12. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Myles O’neill sold 25,000 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $120.00, for a total value of $3,000,000.00. Following the sale, the senior vice president now owns 40,424 shares in the company, valued at approximately $4,850,880. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 8,405 shares of company stock worth $909,004 and sold 1,780,504 shares worth $219,697,912. Corporate insiders own 0.11% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: How does quantitative easing work?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.